First-Line Pirtobrutinib-Venetoclax-Obinutuzumab for CLL
March 5, 2025
The first-line combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in the majority of patients with CLL.
The first-line combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in the majority of patients with CLL.
Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.
Acalabrutinib, venetoclax, and obinutuzumab is a highly active, time-limited frontline therapy for patients with high-risk CLL.
Acalabrutinib plus obinutuzumab had a 100 percent response rate at 14 months and a deep reduction of disease in the bone marrow in treatment-naive CLL.
An interim analysis of the AMPLIFY trial comparing acalabrutinib and venetoclax with or without obinutuzumab for CLL shows improvements in patient survival.
Obinutuzumab can be given alone or in combination with many other medications to treat CLL or SLL.
A new clinical trial is testing the combination of venetoclax with obinutuzumab and magrolimab for relapsed / refractory B-cell lymphomas.
MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.
Chronic lymphocytic leukemia (CLL) patients do better when their first therapy is acalabrutinib based compared to chemoimmunotherapy.